On March 18, 2026, global life sciences platform CSG.BIO announced the acquisition of San Diego-based Hanabusa IVF and Asian Egg Bank, expanding its reproductive health portfolio to span both U.S. coasts. Financial terms were not disclosed. Provident Healthcare Partners advised Hanabusa on the transaction, with Corbel Capital Partners providing financing.

Why It Matters

The fertility industry's consolidation wave mirrors what happened in dental and veterinary care over the past decade — private equity rolling up independent practices into scaled platforms. For the femtech sector, this means fertility startups face an increasingly competitive landscape where PE-backed networks offer integrated services that standalone clinics can't match. The acquisition also highlights growing investor interest in fertility services targeting specific ethnic communities, as Asian Egg Bank addresses documented shortages in donor egg diversity.

Hanabusa IVF, founded by Dr. Peter Fuzesi, specializes in personalized fertility care including mini-IVF and reduced-stimulation protocols — techniques that offer lower-cost alternatives to conventional IVF cycles. Asian Egg Bank serves as a primary resource for intended parents and clinics seeking Asian donor eggs, filling a long-underserved niche in the donor egg market. Together, the two entities bring specialized West Coast fertility capabilities that complement CSG.BIO's existing East Coast presence through the New England Fertility Institute in Stamford, Connecticut.

The deal reflects a broader wave of consolidation sweeping the fertility industry, as private equity-backed platforms seek to build integrated networks connecting IVF clinics, donor programs, biologic storage, and family-building services under single entities. CSG.BIO already operates preservation companies CryoChoice, AlphaCord, and CellSave. The Hanabusa acquisition creates what the company describes as an end-to-end reproductive care platform strategically positioned near major domestic and international travel gateways on each coast.

"Joining CSG.BIO gives us the opportunity to build on what makes us distinctive while gaining the strength of a broader global platform," said Fuzesi, who will continue leading Hanabusa's clinical operations.

Sources

Update — 2026-03-19

Initial entry — story first created.